Epinephrine Market - Trends, Share, Outlook, and Opportunity Analysis, 2018-2026Posted by Rajkumar on June 17th, 2019 Epinephrine also called as adrenaline is a hormone and neurotransmitter produced by the adrenal glands. Epinephrine helps to reverse the effects of anaphylaxis and it is used as the first line of treatment. Auto-injectors are commonly used by individuals suffering from anaphylaxis, as it can be administered by non- medical person. Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2401 The global epinephrine market size was valued at US$ 2,040 million in 2017, and is expected to exhibit a CAGR of 11.0% over the forecast period (2018 – 2026). Increasing support from government and insurance agencies for generic products to propel epinephrine market growth Launch of cost effective generic epinephrine products by the manufacturers is majorly attributed to the high price of EpiPen developed by Mylan NV. The price hike was not accepted by the public, as the drug price increased to more than 400% over a decade. According to data provided by Elsevier Clinical Solutions’ Gold Standard Drug Database, 2016, the cost of EpiPen was US$ 103.50 in 2009, where the price increased up to US$ 264.50 in 2013. The price of the product further increased by 75% costing around US$ 461 in 2015, whereas the price reached to US$ 608.61 in 2016. Furthermore, support of regulatory agencies is expected to streamline the approval of generic copies of drugs, thus allowing the launch of drug substitutes without affecting the clinical effect or safety profile. For instance, in October 2017, the commissioner of FDA announced plans to accelerate development of generic versions that combine a drug and a device. In November 2017, the FDA issued guidance for developing generic copies of complex medicines such as EpiPen to reach the market, without affecting safety and efficacy, thereby providing a lower-cost option and to meet the demand of drug shortages. Market Dynamics Increasing prevalence of food allergies is a major factor driving epinephrine market growth. According to a research conducted by the Centers for Disease Control and Prevention (CDC) in 2013, in the U.S., from 1997 to 2011, food allergies among children increased around by 50%. Moreover, according to the European Academy of Allergy and Clinical Immunology (EAACI), over 17 million people in Europe were affected by food allergy in 2015. For instance, in November 2017, Kaléo, Inc. received the FDA approval for its supplemental New Drug Application (sNDA) for AUVI-Q, the first and only epinephrine auto-injector (EAI) specifically designed for the treatment of life-threatening allergic reactions, including anaphylaxis, in infants and small children weighing 16.5 to 33 pounds. Key Players Major players operating in the global epinephrine market include Mylan N.V., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Impax Laboratories, Inc., Kaleo, Inc., Adamis Pharmaceuticals Corporation, Bausch Health Companies, and ALK- Abello A/S. Market players are focused on launching cost effective versions for patients suffering from severe allergies, requiring constant access to life-saving epinephrine, thereby providing affordable options and propelling the market growth. Browse Complete Report For More Information @ http://bit.ly/2WP9WCP About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us
Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Like it? Share it! More by this author |